KOSPI large cap
SK bioscience
A vaccine developer and contract manufacturer, running flu and shingles vaccines and a global vaccine CMO business. KOSPI large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
302440.KS Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'22-54.5%'23-15.3%'24-22.8%'25+3.5%YTD-27.7%
Money in ▸·
SK bioscience
▸ Money out·
Financials & Segments
- Segments · Vaccines (own) · Contract manufacturing (CMO/CDMO)
Revenue from
No refined links yet.
Pays to
No refined links yet.